SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-043467
Filing Date
2022-02-15
Accepted
2022-02-15 16:47:15
Documents
12
Period of Report
2022-02-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d221882d8k.htm   iXBRL 8-K 35307
  Complete submission text file 0001193125-22-043467.txt   158319

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA lyel-20220211.xsd EX-101.SCH 2839
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE lyel-20220211_lab.xml EX-101.LAB 17979
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lyel-20220211_pre.xml EX-101.PRE 11247
6 EXTRACTED XBRL INSTANCE DOCUMENT d221882d8k_htm.xml XML 3352
Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Filer) CIK: 0001806952 (see all company filings)

IRS No.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40502 | Film No.: 22639832
SIC: 2834 Pharmaceutical Preparations